The stock is in a pronounced downtrend over the past year, with a 1-year price change of -26.60%, significantly underperforming the broader market, which is up 24.0% over the same period. Currently trading at $26.91, the price sits approximately 36% above its 52-week low of $18.29 but remains 36% below its 52-week high of $42.37, indicating it is in the lower-middle portion of its annual range and suggesting the stock has been under significant pressure but may be attempting to find a base. The stock's beta of 0.378 indicates it has been far less volatile than the market during this decline, which is atypical for a biotech and may suggest a lack of speculative momentum or heavy institutional selling pressure. Over the last three months, the stock has shown a strong rebound of 31.78%, sharply contrasting with the 1-year downtrend and the S&P 500's 12.3% gain over the same period, signaling a potential trend reversal or a significant relief rally from deeply oversold conditions. The 1-month performance of +11.24% further confirms this recent positive momentum, significantly outpacing the market's 0.31% gain, suggesting a shift in sentiment, potentially driven by quarterly results or pipeline updates. Key technical support is clearly defined at the 52-week low of $18.29, while resistance lies at the 52-week high of $42.37. A sustained breakout above the recent trading range near $27 would be needed to challenge higher resistance levels, while a breakdown below the $18.29 low would signal a resumption of the primary downtrend. The stock's low beta of 0.378 implies it has exhibited only about 38% of the market's volatility, which, combined with a high short ratio of 8.89, suggests the recent rally could be fueled in part by short covering.

Revenue growth is robust, with Q4 2025 revenue reaching $207 million, representing a 25.55% year-over-year increase, and the quarterly trend shows sequential improvement from $139.3 million in Q1 2025. The revenue is split between Product sales ($101.7 million) and Royalty income ($105.6 million), indicating a diversified revenue stream, though the royalty component, likely from Crysvita, is a significant and stable contributor. This growth trajectory is positive but must be weighed against the company's substantial and ongoing losses. The company remains deeply unprofitable, with a Q4 2025 net loss of $129 million, translating to an EPS of -$1.29, and a trailing twelve-month free cash flow of -$472 million. Despite a high gross margin of 83.8% in the latest quarter, operating expenses, particularly R&D which was $203 million in Q4, completely erode this, resulting in a net margin of -85.4% and negative EBITDA of -$105.2 million. The balance sheet shows a current ratio of 2.48, indicating sufficient short-term liquidity, but the debt-to-equity ratio is a negative -15.95, which is an unusual figure typically resulting from accumulated deficits eroding shareholder equity into negative territory. Return on Equity is reported at 7.19%, but this positive figure is likely an artifact of negative equity and should be viewed with extreme caution. The persistent and large negative free cash flow of -$472 million TTM highlights the company's continued reliance on external financing to fund operations and growth, representing a key financial risk.